Works matching IS 13524585 AND DT 2022 AND VI 28 AND IP 1
Results: 19
Charting a global research strategy for progressive MS—An international progressive MS Alliance proposal.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 16, doi. 10.1177/13524585211059766
- By:
- Publication type:
- Article
Administrative data for observational research in multiple sclerosis: Opportunities and challenges.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Depression readmission risk is elevated in multiple sclerosis compared to other chronic illnesses.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 139, doi. 10.1177/13524585211051316
- By:
- Publication type:
- Article
Aquaporin-4 antibody neuromyelitis optica spectrum disorder: A paraneoplastic disease?
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 163, doi. 10.1177/13524585211039755
- By:
- Publication type:
- Article
SARS-CoV-2 antibodies in multiple sclerosis patients depending on the vaccine mode of action?
- Published in:
- 2022
- By:
- Publication type:
- Letter
Pediatric paraneoplastic neuromyelitis optica spectrum disorder associated with ovarian teratoma.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 160, doi. 10.1177/13524585211037582
- By:
- Publication type:
- Article
Mild gray matter atrophy in patients with long-standing multiple sclerosis and favorable clinical course.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 154, doi. 10.1177/13524585211019650
- By:
- Publication type:
- Article
Optic chiasm involvement in AQP-4 antibody–positive NMO and MOG antibody–associated disorder.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 149, doi. 10.1177/13524585211011450
- By:
- Publication type:
- Article
Effect of continuous positive airway pressure treatment of obstructive sleep apnea-hypopnea in multiple sclerosis: A randomized, double-blind, placebo-controlled trial (SAMS-PAP study).
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 82, doi. 10.1177/13524585211010390
- By:
- Publication type:
- Article
Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 111, doi. 10.1177/13524585211010294
- By:
- Publication type:
- Article
Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 102, doi. 10.1177/13524585211010097
- By:
- Publication type:
- Article
CSF chitinase 3-like 1 is associated with iron rims in patients with a first demyelinating event.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 71, doi. 10.1177/13524585211010082
- By:
- Publication type:
- Article
Current status of neuroprotective and neuroregenerative strategies in multiple sclerosis: A systematic review.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 29, doi. 10.1177/13524585211008760
- By:
- Publication type:
- Article
Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 61, doi. 10.1177/13524585211008743
- By:
- Publication type:
- Article
Aging with multiple sclerosis: A longitudinal study of physical function, mental health, and memory in two cohorts of US women.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 121, doi. 10.1177/13524585211007739
- By:
- Publication type:
- Article
Central vein sign and other radiographic features distinguishing myelin oligodendrocyte glycoprotein antibody disease from multiple sclerosis and aquaporin-4 antibody-positive neuromyelitis optica.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 49, doi. 10.1177/13524585211007086
- By:
- Publication type:
- Article
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 93, doi. 10.1177/13524585211005657
- By:
- Publication type:
- Article
Impact of COVID-19 on multiple sclerosis care and management: Results from the European Committee for Treatment and Research in Multiple Sclerosis survey.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 132, doi. 10.1177/13524585211005339
- By:
- Publication type:
- Article
Progressive multifocal leukoencephalopathy in dimethyl fumarate-treated multiple sclerosis patients.
- Published in:
- Multiple Sclerosis Journal, 2022, v. 28, n. 1, p. 7, doi. 10.1177/1352458520949158
- By:
- Publication type:
- Article